

(12)特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2005年2月3日 (03.02.2005)

PCT

(10) 国際公開番号
WO 2005/009470 A1

(51) 国際特許分類⁷: A61K 45/00, 31/7105, 31/711, 38/45, 39/395, 48/00, A61P 9/04, G01N 33/15, 33/50

府大阪市中央区本町橋2番5号マイドームおおさか内
Osaka (JP).

(21) 国際出願番号: PCT/JP2004/011124

(72) 発明者; および

(22) 国際出願日: 2004年7月28日 (28.07.2004)

(75) 発明者/出願人(米国についてのみ): 大津欣也 (OTSU, Kinya), 西田和彦 (NISHIDA, Kazuhiko), 山口修 (YAMAGUCHI, Osamu), 横口義治 (HIGUCHI, Yoshiharu), 一條秀憲 (ICHIJO, Hidenori).

(25) 国際出願の言語: 日本語

(74) 代理人: 特許業務法人池内・佐藤アンドパートナーズ (IKEUCHI SATO & PARTNER PATENT ATTORNEYS); 〒530-6026 大阪府大阪市北区天満橋1丁目8番30号OAPタワー26階 Osaka (JP).

(26) 国際公開の言語: 日本語

(81) 指定国(表示のない限り、全ての種類の国内保護が可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM,



(30) 優先権データ:
特願2003-281281 2003年7月28日 (28.07.2003) JP

(71) 出願人(米国を除く全ての指定国について): 財團法人大阪産業振興機構 (OSAKA INDUSTRIAL PROMOTION ORGANIZATION) [JP/JP]; 〒5400029 大阪

[続葉有]

(54) Title: REMEDY FOR CARDIAC FAILURE COMPRISING ASK1 INHIBITOR AS THE ACTIVE INGREDIENT AND METHOD OF SCREENING THE SAME

(54) 発明の名称: ASK1阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法



E. LVDD: 左室拡張末期径

F. LVIDs: 左室収縮末期径

G. FS: 左室内径短縮率

A...4 WEEKS AFTER MYOCARDIAL INFARCTION

B...WILD TYPE n=14

C...p<0.05 TO WILD TYPE

D...4 WEEKS AFTER TAC

E...LVDD: LEFT VENTRICULAR INTERNAL DIAMETER IN END DIASTOLE

F...LVIDs: LEFT VENTRICULAR INTERNAL DIAMETER IN END SYSTOLE

G...FS: LEFT VENTRICULAR FRACTIONAL SHORTENING

(57) Abstract: It is intended to provide a drug for at least either prevention or treatment for cardiac failure whereby cardiac depression and the onset of cardiac failure in ventricular remodeling can be inhibited and a method of screening the same. Namely, a drug for at least either prevention or treatment for cardiac failure which contains, as the active ingredient, a compound inhibiting the expression of the function of ASK1 protein in myocardial cells; and a method of screening a drug for at least either prevention or treatment for cardiac failure which is a screening method involving the step of selecting a medicinal composition for at least either the prevention or treatment for cardiac failure from candidate compounds for the drug with the use of the inhibition of the expression of the function of ASK1 protein as an indication. As Fig. 1 shows, ventricular diastole in ventricular remodeling after myocardial infarction or pressure loading can be lessened by eliminating ASK1 protein, which makes it possible to prevent or treat cardiac failure.

WO 2005/009470 A1

[続葉有]